Holen Sie sich die Stockscreener-App
7.36
1.94%
0.14
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
RNAC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
H.C. Wainwright reiterates Cartesian Therapeutics stock rating at buy By Investing.com - Investing.com Canada
RNAC Reiterated by Needham -- Price Target Maintained at $40 - GuruFocus
Needham reiterates Buy rating on Cartesian Therapeutics, $40 price target - TradingView
Cartesian Therapeutics Reports Encouraging Descartes-08 Retreatment Data - TipRanks
Cartesian Therapeutics Unveils Phase 2 Descartes-08 Retreatment Results in Myasthenia Gravis Patients - kalkinemedia.com
Cartesian Therapeutics presents Descartes-08 retreatment data at AANEM for ongoing Phase 3 MG trial - Traders Union
Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis - TradingView
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis - GlobeNewswire
Cartesian Therapeutics Inc. (NASDAQ: RNAC) Share Price, RNAC Stock News, RNAC Share Price & Updates - Kalkine
RNAC Q2 2026 Earnings: Cartesian Therapeutics Reports Surprise Positive EPS of $0.61, Beating Estimates by 168.86%Profit Margin Analysis - dars.gov.et
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Three investor events are expected in September. Two talks may stream online. - Stock Titan
Insiders Who Sold Cartesian Therapeutics Made The Right Call As Market Cap Slides By US$33m - simplywall.st
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock? - qz.com
Cartesian (RNAC) Price: Retreats 1.86% to $10.04 at the Close; Technical View: Traders Can Monitor the $9.54-$10.54 Range in the Latest ReadingPrice Target - vinanet.vn
Cartesian (RNAC) Earnings Report: EPS Comes in Above Forecast in the Latest Reading; Market Reaction: The Stock Ends Up 14.02% in the Latest SessionEarnings Quality Score - vinanet.vn
Cartesian (RNAC) Results at a Glance: EPS Prints Above Forecast in the Current Update; Latest Reaction: The Stock Gains 9.78% in the Latest ReadingCore Business Growth - vinanet.vn
Cartesian (RNAC) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison in the Latest Session; Closing Reaction: The Stock Gains 0.22% at the CloseMid-Term Outlook - vinanet.vn
RNAC Reiterated by Wedbush -- Rating Maintained at Outperform - GuruFocus
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | RNAC | US8162123025 - marketscreener.com
Barclays PLC (RNAC) discloses 1.76M-share, 5.99% holding in Cartesian Therapeutics - Stock Titan
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Lower Earnings Estimates for RNAC - MarketBeat
Cartesian Therapeutics (RNAC) Slips 2.85% as Shares Test Key Support at $8.08Weekly Profile - dars.gov.et
Cartesian Therapeutics Advances RNA Cell Therapy Pipeline; Wedbush Sets $38 Price Target - RTTNews
RNAC Q2 2026 Earnings: Positive EPS Surprise Masks Pre-Revenue Biotech ChallengesProfit Cycle Analysis - dars.gov.et
Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
A Quick Look at Today's Ratings for Cartesian Therapeutics(RNAC.US), With a Forecast Between $25 to $44 - Moomoo
Cartesian Therapeutics Inc (RNAC) Stock News Today - TradingKey
Cartesian Therapeutics earnings beat by $1.34, revenue fell short of estimates - Investing.com Canada
Cartesian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cartesian Therapeutics Q2 2026 earnings: R&D spending rises as Phase 3 advances - TradingKey
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership - Quiver Quantitative
Cartesian Therapeutics reports Q2 2026: $149.3M cash; net income $15.8M; Phase 3 MG data expected 1Q27 - TradingView
Cartesian Therapeutics (Nasdaq: RNAC) Q2 earnings boosted by CVR revaluation - Stock Titan
Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC - Moomoo
Cartesian Therapeutics Q2 Net Income Reaches $15.8 Million As Pipeline Advances - Quiver Quantitative
RNAC Q2'26 Earnings: EPS estimate is (0.88) USD - TradingView
Cartesian Therapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
Price to sales forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cartesian Therapeutics (NASDAQ:RNAC) Raised to Hold at Zacks Research - MarketBeat
RNAC Q2'26 Earnings: revenue estimate is 179.67K USD - TradingView
Cartesian Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAC - TradingView
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 1.1%Here's What Happened - MarketBeat
Cartesian Therapeutics Inc (RNAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Cash Flow - TradingKey
Cartesian Therapeutics, Inc. Revenue Breakdown – FWB:1S70 - TradingView
Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cartesian Therapeutics Inc (RNAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RNAC|Cartesian Therapeutics Inc|Price:10.190|Chg%:-0.190 - TradingKey
Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cartesian Therapeutics Inc (RNAC) Balance Sheet - TradingKey
Cartesian Therapeutics Inc (RNAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RNAC|Cartesian Therapeutics Inc|Price:7.780|Chg%:-0.100 - TradingKey
TradingKey - TradingKey
Cartesian Therapeutics, Inc. Revenue Breakdown – LS:A407YS - TradingView
ETFs Investing in Cartesian Therapeutics, Inc. Stocks - TradingView
JPMorgan Chase & Co. (RNAC) discloses 4.8% beneficial stake in Cartesian Therapeutics - Stock Titan
RNAC Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue ChallengesHealthcare Earnings Report - dars.gov.et
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):